Wang B
Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave
COVID-19 vaccines have been essential in bringing the pandemic under control. They have shown to be highly efficacious against severe diseases
ReadDefining neutralization and allostery by antibodies against COVID-19 variants
The changing landscape of SARS-CoV-2 Spike protein is linked to the emergence of variants, immune-escape and reduced efficacy of the existing repertoire of anti-viral antibodies.
ReadDefining neutralization and allostery by antibodies against COVID-19 variants
The changing landscape of SARS-CoV-2 Spike protein is linked to the emergence of variants, immune-escape and reduced efficacy of the existing repertoire of anti-viral antibodies. The functional activity of neutralizing antibodies is linked to their quaternary changes occurring as a result of antibody-Spike trimer interactions. Here, we reveal the conformational dynamics and allosteric perturbations linked to binding of novel human antibodies and the viral Spike protein.
ReadHeterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant
The SARS-CoV-2 Omicron recombinant XBB subvariant was first detected in September 2022, and rapidly spread across South-East Asia, notably overtaking BA.5 to become the dominant variant in Singapore.
ReadResistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
SARS-CoV-2 was first detected in late December 2019, however, in the few months that followed, the resultant COVID-19 disease has developed into a devastating pandemic around the world [[1]]. This has led to a race to produce a safe and efficacious vaccine in record time.
ReadStructural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is initiated by binding of the viral Spike protein to host receptor angiotensin-converting enzyme 2 (ACE2), followed by fusion of viral and host membranes. Although antibodies that block this interaction are in emergency use as early coronavirus disease 2019 (COVID-19) therapies, the precise determinants of neutralization potency remain unknown.
Read